number remain equal-
support recent downgrad see
immedi revers trend risk remain balanc
view lower estim pt remain equal-weight
preliminari result indic slower commerci traction focu
recent downgrad report preliminari result
sale vs mse includ us vs mse
ou vs mse reduc guidanc
midpoint earli see exhibit
ascertain result impli share competitor report
downgrad equal-weight two week ago focus limit clinic
differenti commerci traction near-term clinic catalyst void risk
senza superior saluda data boston litig yesterday call
focus hire challeng us slower intern growth
updat boston ip litig timelin discuss
slower hire trend compound sale attrit may suggest limit
commerci differenti manag cite slower hire reason
lower guidanc howev hire normal impact busi month
forward think weak hire trend net rep add vs net
rep add contributor guidanc reduct compound
sale attrit remain elev near manag knew
year-end hire figur attrit remain constant year impli
dynam may play attrit definit impact senior
rep creat neg mix problem even rep hire normal
difficulti penetr new market focu call
remain concern store sale growth inabl gain share
coupl elev attrit difficulti hire suggest materi chang
competit landscap and/or devic differenti stabil
improv largest chang last regardless
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
clear reson physician rep
structur issu may revers quickli
drive intern growth lower guidanc intern
lower high-singl digit low-doubl digit cc growth low-singl
digit cc growth certain ex-u market central europ take longer
recov re-establish busi follow reimburs budget issu
major ex-u market uk germani australia continu grow
compani believ recent uk decis neg
impact trend grow market intern
appreci market cost-focus tradit harder
sell expens recharg product competit primari
cell offer domin market notwithstand wonder
limit clinic differenti hamper ex-u share gain market
longev product
next ip catalyst summari judgement could come earli
week final rule summari judgement see updat nevro/boston
patent disput come come week trial schedul
begin novemb juri rule infring valid
potenti damag post-trial matter injunct unresolv
issu appeal process take place like earli believ
hf ip defens per draft summari judgement hard handicap
risk overhang lift
lower estim pt make materi chang
previous consensu model reflect slower commerci traction hire
along spend includ reduc top-line estim
model
project break-even ebitda vs prior includ litig expens
take prudent approach spend estim reflect bp
us share gain bp reflect saluda
boston ip risk discuss dcf-base price target move vs
prior primari chang dcf includ peak margin vs
prior ww us share vs prior
price target consist base busi expans
maintain equal-weight balanc risk/reward limit near term upsid
share sinc juli trade sale
appreci inexpens growth stock attract vertic remain
equal-weight sever reason rep attrit hire challeng
symptom street still focus root caus competit
intensifi primarili intellis/evolv boston
wavewrit also potenti saluda data come januari
edg boston ip litig neg
risk/reward skew clinic catalyst could drive enthusiasm
pdn/nsrbp unlik interim see balanc risk-
reward lose ip saluda data signific see bear case
scenario play top-line estim high-singl digit declin y/i
growth ev/sal multipl drive valuat separ nevro
abl recov put sale line prior guidanc
see multipl prior sale estim
appropri drive valuat balanc remain equal-
weight price target impli limit upsid near term
pleas see insid detail model chang market model
price target deriv base busi discount
cash flow valuat assum oper margin
wacc termin growth rate yield
ad expans
share gain expans continu rapid share gain allow
captur market share time margin reach
addit make substanti progress expans
painlessli disrupt captur us market
share gain labor given competit market
track gain us share time clinic catalyst around
expans like materi leav catalyst void
competit respons creat headwind progress date low-hang
fruit futur uptak prove challeng market prove
sensit market clinic data at-risk competit launch caus
disrupt market us market share remain flat top
high teen valuat contract
guidanc look achiev us
howev path addit share gain
harder given increas
competit competitor traction
clinic data expand
key data pain diabet neuropathi
non-surg back come
suggest clinic catalyst void
interim
senza superior could risk later
year competitor data less
concern tail risk exist litig
pt ww share increas
revenu
pt us share increas
revenu
pt us market growth assum
pro rata share increas revenu
bp
competit launch data on-going
risk achiev price
acceler competitor product
develop product uptak
current rep/physician relationship
stronger anticip
confid ip posit
patent litig may key risk time
sale
sale
sale
sale
sale
sale
accret redeem convert prefer stock redempt valu
dollar million except per share data
good sold
dollar million except per share data
dollar million except per share data
accumul comprehens loss
dollar million except per share data
non-cash loss extinguish debt
payment origin issu discount
provis doubt account
write-down inventori
unreal loss foreign currenc transact
purchas short-term invest
proce matur short-term invest
chang restrict cash
proce issuanc common stock underwritten public offer
proce issuanc convert note
convert note initi issuanc discount debt issuanc cost
proce issuanc warrant
purchas convert note hedg
repay debt
purchas common stock proce issuanc common stock stock option exercis
begin period
end period
sale
sale
chang work capit
sale
pv
weight averag capit wacc
equiti
margin debt
after-tax debt
pv free flow
pv termin valu
pv tax benefit
mv equiti invest
one year valu
total
present valu
pv
pv termin valu
one year valu
million
